Home delivery of antiretroviral drugs for people living with HIV (PLHIV) in Indonesia, Laos, Nepal, and Nigeria: Implications of COVID-19 experiences for post-pandemic decentralized ARV delivery

Moses Bateganya,¹ Theresa Hoke,¹ Otoyo Toyo,² Caroline Francis,³ Laurent Ferradini,³ Bhagawan Shrestha,⁴ Phayvieng Philakone,⁵ Satish Raj Pandey,⁶ Navindra Persaud,⁷ Michael Cassel,⁸ Rose Wilcher,¹ Hally Mahler⁷

BACKGROUND

COVID-19-imposed health facility closures and travel restrictions have necessitated innovative service delivery mechanisms for people with chronic health conditions including HIV. Home delivery (HD) is an out-of-facility differentiated service delivery model that can ensure treatment continuity.^{1,2} The USAID- and PEPFAR-supported Meeting Targets and Maintaining Epidemic Control (EpiC) project, led by FHI 360, in Indonesia, Laos, Nepal, and Nigeria introduced HD of antiretrovirals (ARVs) for HIV treatment continuity. A 2020 program review revealed HD to be feasible and acceptable across the four countries, with 19% to 51% of eligible clients receiving ARVs through HD.³ We report on continued HD in 2021, the pandemic's second year, and present implications for decentralized drug delivery (DDD) beyond emergency circumstances.

METHODS

Throughout 2021, all four countries continued ARV home delivery mechanisms initiated in 2020. In Indonesia, the Jakarta Provincial Health Office continued to support Jak-Anter, a home-based ARV delivery system that uses ride-based apps and transport courier services. In Laos and Nepal, HD conducted by community health workers continued, with the numbers of clients using the service varying with pandemic intensity. In Akwa Ibom State, Nigeria, clients were progressively transferred to alternative DDD models with 21 facilities continuing to provide HD (versus 51 in 2020) to only those individuals not reachable through other models.



EPE407

RESULTS

In 2021, in project-supported areas of Indonesia, Laos, and Nepal, 29.8%, 47.0%, and 28.4% of individuals, respectively, received ARVs through HD (Figure 1). In Nigeria, HD was restricted to only 12% of clients on ARVs in Mbo Local Government Area who could not go to the facility. In the four countries, service


delivery guidelines were adjusted to support HD but national policy changes needed to sustain the approach were still not made. While initial enrollment was slow, uptake improved following demand creation (through social media, expert clients, and continuous stakeholder engagement).

FIGURE 1. Percentage of PLHIV receiving home delivery in participating project sites, 2020 and 2021

Home delivery teams setting off in Akwa Ibom, Nigeria

CONCLUSIONS

Understaffing in health facilities, exacerbated by COVID-19 infection among health care providers, made ARV HD a valuable service alternative. Six-month dispensing allows HD to be practical and affordable but requires consistent ARV stocks. In addition, the countries continuing ARV HD rely on donor funding and external technical assistance, yet mechanisms for sustaining and scaling the approach without external support are not in place. New mechanisms for financing, supply chain management, staff training and supervision, and client sensitization are needed to implement HD at scale. Options for decentralized service delivery will be especially important for future service disruptions caused by other pandemics, natural disasters, or civil unrest.



AUTHOR AFFILIATIONS ¹ FHI 360, Durham, NC, United States ²Achieving Health Nigeria Initiative, Akwa Ibom, Nigeria ³ FHI 360, Jakarta, Indonesia ⁴ FHI 360, Kathmandu, Nepal ⁵ FHI 360, Vientiane, Laos ⁶ FHI 360, Abuja, Nigeria ⁷ FHI 360, Washington, DC, United States ⁸ FHI 360, Hanoi, Vietnam

REFERENCES

¹ PEPFAR. PEPFAR 2022 country and regional operational plan (COP/ROP) guidance for all PEPFAR-supported countries. Washington: PEPFAR; 2022. Available from: https://www.state.gov/wp-content/uploads/2022/02/COP22-Guidance-Final 508-Compliant-3.pdf.

² PEPFAR. PEPFAR Solutions Platform [Internet]. How home delivery of antiretroviral drugs ensured uninterrupted HIV treatment during COVID-19 and can be optimized to address unique client needs and other emergencies. 2021 Nov 10 [cited 2022 Jun 6]. Available from: https://www.pepfarsolutions.org/solutions/2021/11/5/ora.

³ Hoke T, Bateganya M, Toyo O, Francis C, Shrestha B, Philakone P, et al. How home delivery of antiretroviral drugs ensured uninterrupted HIV treatment during COVID-19: experiences from Indonesia, Laos, Nepal, and Nigeria. Glob Health Sci Pract. 2021 Dec 9;(4):978-89. doi: 10.9745/GHSP-D-21-00168.

CONTACT INFORMATION FOR LEAD AUTHOR

Moses Bateganya, Technical Director, HIV Programs, FHI 360, mbateganya@fhi360.org

Presented at AIDS 2022 – The 24th International AIDS Conference

www.fhi360.org/projects/meeting-targets-and-maintaining-epidemic-control-epic







This work was made possible by the generous support of the American people through the United States Agency for International Development (USAID) and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). The contents are the responsibility of the EpiC project and do not necessarily reflect the views of USAID, PEPFAR, or the United States Government.

EpiC is a global cooperative agreement (7200AA19CA00002) led by FHI 360 with core partners Right to Care, Palladium International, and Population Services International (PSI).

